Institut Pasteur Korea, DNDi Partner in Neglected Diseases Screening Effort | GenomeWeb

NEW YORK (GenomeWeb News) – The international non-profit Drugs for Neglected Diseases Initiative (DNDi) and the Institut Pasteur Korea (IP-K) will collaborate to screen for and examine molecules that may be used as new treatments for certain "neglected" diseases, IP-K said today.

The two-year research agreement will focus on studying molecules that could be developed into treatments for leishmaniasis, which kills around 20,000 to 30,000 people per year, and Chagas disease, which affects around seven to eight million people every year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.